SDZXF (Sandoz Group AG) Tax Expense: $293 Mil (TTM As of Dec. 2025)


SDZXF Sandoz Group AG SDZXF
18 GF Score
Price $89.55
! 6 Warning Signs
View Full Analysis

What is Sandoz Group AG Tax Expense?

Sandoz Group AG SDZXF 18 Tax Expense is $293 Mil as of Dec. 2025. GuruFocus rates SDZXF with a GF Score™ of 18/100. The stock has 6 warning signs investors should review.

Sandoz Group AG's tax expense for the months ended in Dec. 2025 was $166 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was $293 Mil.

Sandoz Group AG  (OTCPK:SDZXF) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.

Sandoz Group AG Tax Expense Related Terms

Sandoz Group AG Tax Expense Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Tax Expense Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Tax Expense
252.00 50.00 -12.00 293.00

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Expense Get a 7-Day Free Trial -76.00 53.00 -65.00 127.00 166.00
SDZXF
18GF Score
Sandoz Group AG SDZXF
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $293 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of $293 Mil mean?
Sandoz Group AG (SDZXF) has a Tax Expense of $293 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Tax Expense too high?
Sandoz Group AG's current Tax Expense is $293 Mil. Overall, Sandoz Group AG has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Tax Expense compare to ZTS and UTHR?
Sandoz Group AG's Tax Expense of $293 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Drug Manufacturers company?
A good Tax Expense depends on the Drug Manufacturers industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Tax Expense is $293 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (SDZXF) has a current Tax Expense of $293 Mil. The current Tax Expense is $293 Mil. Sandoz Group AG's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current Tax Expense is $293 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
18GF Score

Get the complete analysis for SDZXF

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.55
Price